Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrince, Miles-
dc.contributor.otherVan Der Weyden, Carrie-
dc.contributor.otherPileri, Stefano-
dc.contributor.otherFeldman, Andrew-
dc.contributor.otherWhisstock, James-
dc.identifier.citationBlood Cancer J. 2017 Sep 8;7(9):e603en_US
dc.description.abstractCD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Given the restriction of CD30 to certain tumor types, the logical extension of this has been to attempt to exploit it as a therapeutic target. The efficacy of naked anti-CD30 antibodies in practice was, however, modest. Moreover, combinations with bacterial toxins and radioimmunoconjugates have also had limited success. The development of the antibody-drug compound brentuximab vedotin (BV), however, has rejuvenated interest in CD30 as a tumor target. Phase I and II clinical trials in Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T cell lymphoma, and even CD30-expressing B-cell lymphomas, have shown the compound is well tolerated, but more importantly, able to deliver meaningful disease control even in patients with multiply relapsed or refractory disease. FDA approval has been granted for its use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A recent phase III trial of BV in cutaneous T-cell lymphoma has confirmed its superiority to standard of care therapies. In this manuscript, we explore the history of CD30 as a tumor marker and as a therapeutic target, both in the laboratory and in the clinic, with a view to understanding future avenues for further study.en_US
dc.publisherNature Publishing Groupen_US
dc.subjectHematopoietic Malignanciesen_US
dc.subjectBrentuximab Vedotinen_US
dc.subjectTumor Markeren_US
dc.subjectTherapeutic Targeten_US
dc.subjectTumor Necrosis Factor Receptoren_US
dc.subjectCell Survivalen_US
dc.subjectHodgkin Lymphomaen_US
dc.subjectPeripheral T-Cell Lymphomaen_US
dc.subjectCutaneous T-Cell Lymphomaen_US
dc.subjectDisease Controlen_US
dc.subjectAnaplastic Large Cell Lymphomaen_US
dc.subjectFuture Directionsen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleUnderstanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBlood Cancer Journalen_US
dc.description.affiliatesDepartment of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.description.affiliatesHaematopathology Unit, European Institute of Oncology, Milan, Italyen_US
dc.description.affiliatesBologna University School of Medicine, Bologna, Italyen_US
dc.description.affiliatesDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USAen_US
dc.description.affiliatesARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australiaen_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australiaen_US
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.